paroxetine has been researched along with dextromethorphan in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Burke, M; Harvey, AT | 1 |
| Brown, TM; Finkelstein, JA; Magoon, MR; Mareth, TR; Skop, BP | 1 |
| Bowery, NG; Meoni, P; Tortella, FC | 1 |
| Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 2 |
| Avenoso, A; Facciolà, G; Scordo, MG; Spina, E | 1 |
| Anziano, RJ; Apseloff, G; Demattos, SB; Gerber, N; Wilner, KD | 1 |
| Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J | 1 |
| Balogh, A; Eberhardt, AM; Härtter, S; Hiemke, C; Kirsch, M; Kuhn, UD; Maurer, I; Merkel, U; Volz, HP; Wenda, B | 1 |
| Pope, LE; Schoedel, KA; Sellers, EM | 1 |
| Isoherranen, N; Ke, AB; Nallani, SC; Rostami-Hodjegan, A; Unadkat, JD; Zhao, P | 1 |
| Juřica, J; Žourková, A | 1 |
| Howland, RH | 1 |
| Daali, Y; Desmeules, J; Lenglet, S; Matthey, A; Storelli, F; Thomas, A | 1 |
| Ahl, B; Anghelescu, IG; Wilhelm, R | 1 |
| Daali, Y; Desmeules, J; Storelli, F | 2 |
1 review(s) available for paroxetine and dextromethorphan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 trial(s) available for paroxetine and dextromethorphan
| Article | Year |
|---|---|
CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Topics: Adult; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Reference Values; Sertraline | 1999 |
No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Drug Interactions; Enzyme Inhibitors; Female; Humans; Isoenzymes; Male; Morpholines; Paroxetine; Phenotype; Reboxetine; Time Factors | 1999 |
CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Topics: Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Humans; Isoenzymes; Paroxetine; Phenotype; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2000 |
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Topics: Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Fluvoxamine; Genotype; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Genotype; Humans; Male; Mixed Function Oxygenases; Morpholines; Mutation; Paroxetine; Phenotype; Reboxetine; Reference Values; Selective Serotonin Reuptake Inhibitors | 2007 |
Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Topics: Adult; Affective Symptoms; Dextromethorphan; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Paroxetine; Quinidine | 2012 |
Dynamics and persistence of CYP2D6 inhibition by paroxetine.
Topics: Adolescent; Adult; Aged; Alprazolam; Anxiety; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Dextromethorphan; Dextrorphan; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Young Adult | 2013 |
16 other study(ies) available for paroxetine and dextromethorphan
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Drug Interactions; Female; Humans; Mixed Function Oxygenases; Paroxetine; Serotonin; Syndrome | 1995 |
The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease.
Topics: Acetaminophen; Acute Disease; Akathisia, Drug-Induced; Blood Platelets; Dextromethorphan; Diagnosis, Differential; Doxylamine; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Ephedrine; Humans; Hypertension; Male; Middle Aged; Myoclonus; Nonprescription Drugs; Paroxetine; Peripheral Vascular Diseases; Promethazine; Pseudoephedrine; Sweating; Syndrome | 1994 |
An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine.
Topics: Animals; Autoradiography; Binding Sites; Brain; Dextromethorphan; Ions; Kinetics; Male; Paroxetine; Rats; Rats, Wistar; Serotonin; Sodium; Tritium | 1997 |
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Female; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
Topics: Clonidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Female; Humans; Models, Biological; Paroxetine; Pregnancy; Theophylline | 2013 |
Deuterated Drugs.
Topics: Deuterium; Dextromethorphan; Humans; Paroxetine; Prescription Drugs; Tetrabenazine | 2015 |
Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Topics: Adolescent; Adult; Alleles; Analgesics, Opioid; Antitussive Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Interactions; Duloxetine Hydrochloride; Female; Genotype; Heterozygote; Homozygote; Humans; Male; Paroxetine; Pharmacogenomic Variants; Phenotype; Tramadol; Young Adult | 2018 |
Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia.
Topics: Aged; Aggression; Cannabinoid Receptor Agonists; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dronabinol; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Lewy Body Disease; Male; Paroxetine; Psychomotor Agitation | 2017 |
Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Topics: Alleles; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Demethylation; Dextromethorphan; Duloxetine Hydrochloride; Genotype; Humans; Microsomes, Liver; Paroxetine | 2019 |
Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions.
Topics: Adult; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP2D6; Dextromethorphan; Drug Interactions; Duloxetine Hydrochloride; Humans; Male; Models, Biological; Paroxetine; Pharmacogenomic Variants; Young Adult | 2019 |